



# RESEARCH2REALITY

Shining a light on research & innovation.

## A Century Later, An Improvement on Daily Aspirin

An interview with **Population Health Research Institute** researchers:

**John Eikelboom**, Hematologist

**Salim Yusuf**, Cardiologist

and **Sonia Anand**, Cardiologist

### John Eikelboom

COMPASS, which stands for Cardiovascular Outcomes in People using Anticoagulation Strategies, is a global randomized trial: 33 countries, over 600 sites.

### Salim Yusuf

COMPASS is a study where we took people with evidence of vascular disease - stroke, or peripheral artery disease, or a heart attack. These people are at risk of future events, even though they may be getting aspirin. So in the COMPASS study, we tested, can we improve on aspirin? And aspirin has been king for nearly a hundred years.

### Sonia Anand

And the exciting part is we certainly found that the low-dose rivaroxaban used together with aspirin was superior to aspirin alone. That's the first time we have a therapy that prevents both cardiovascular complications and limb complications.

TODAY'S RESEARCH. TOMORROW'S REALITY.

